AU2001251358A1 - Prion-binding ligands and methods of using same - Google Patents

Prion-binding ligands and methods of using same

Info

Publication number
AU2001251358A1
AU2001251358A1 AU2001251358A AU5135801A AU2001251358A1 AU 2001251358 A1 AU2001251358 A1 AU 2001251358A1 AU 2001251358 A AU2001251358 A AU 2001251358A AU 5135801 A AU5135801 A AU 5135801A AU 2001251358 A1 AU2001251358 A1 AU 2001251358A1
Authority
AU
Australia
Prior art keywords
prion
methods
same
binding ligands
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001251358A
Inventor
Ruben Carbonell
David J Hammond
Honglue Shen
Vite Rose Wiltshire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VI Technologies Inc
Original Assignee
VI Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VI Technologies Inc filed Critical VI Technologies Inc
Publication of AU2001251358A1 publication Critical patent/AU2001251358A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001251358A 2000-04-05 2001-04-05 Prion-binding ligands and methods of using same Abandoned AU2001251358A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54318800A 2000-04-05 2000-04-05
US09543188 2000-04-05
PCT/US2001/011150 WO2001077687A2 (en) 2000-04-05 2001-04-05 Prion-binding peptidic ligands and methods of using same

Publications (1)

Publication Number Publication Date
AU2001251358A1 true AU2001251358A1 (en) 2001-10-23

Family

ID=24166952

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001251358A Abandoned AU2001251358A1 (en) 2000-04-05 2001-04-05 Prion-binding ligands and methods of using same

Country Status (7)

Country Link
US (1) US20040186273A1 (en)
EP (1) EP1272509A2 (en)
JP (1) JP2003530554A (en)
AU (1) AU2001251358A1 (en)
CA (1) CA2405568A1 (en)
IL (1) IL152116A0 (en)
WO (1) WO2001077687A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002097444A2 (en) 2001-05-31 2002-12-05 Arete Associates Misfolded protein sensor method
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
ES2460641T3 (en) * 2002-12-03 2014-05-14 Pathogen Removal And Diagnostic Technologies, Inc. Prion protein ligands and use procedures
FR2849205B1 (en) 2002-12-20 2005-02-11 Afssa METHOD FOR AMPLIFYING PRPSC DETECTION AND USE OF A MACROCYCLIC ADJUVANT LIGAND FOR SUCH AMPLIFICATION
US20040192887A1 (en) * 2003-03-25 2004-09-30 Ralph Zahn PH-dependent polypeptide aggregation and its use
US7510848B2 (en) 2003-04-04 2009-03-31 North Carolina State University Prion protein binding materials and methods of use
CA2521438C (en) * 2003-04-04 2014-03-25 Steven J. Burton Prion protein binding materials and methods of use
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
CA2535261C (en) 2003-08-13 2015-11-24 Chiron Corporation Prion-specific peptide reagents
RU2267496C2 (en) 2004-01-15 2006-01-10 Сергей Иванович Черныш Anti-tumor and antiviral peptides
EP1571449A1 (en) * 2004-03-01 2005-09-07 Stichting Sanquin Bloedvoorziening Prion immunoassay and separation method
WO2006009920A2 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
GB0416699D0 (en) 2004-07-27 2004-09-01 Prometic Biosciences Ltd Prion protein ligands and methods of use
US20090099343A1 (en) * 2005-01-13 2009-04-16 David Peretz Isolation of pathogenic prions
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
CN101156068B (en) 2005-02-15 2015-03-18 阿德利夫股份有限公司 Method for detecting misfolded proteins and prions
BRPI0611811A2 (en) 2005-06-10 2008-12-09 Prometic Biosciences Ltd protein binding binders
US7834144B2 (en) 2005-09-09 2010-11-16 Novartis Ag Prion-specific peptoid reagents
KR20080074914A (en) * 2005-10-28 2008-08-13 알리콘 아게 Method for concentrating, purifying and removing prion protein
WO2007128450A1 (en) * 2006-05-02 2007-11-15 Alicon Ag Identification of prion proteins in milk
US8673579B2 (en) 2006-07-28 2014-03-18 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
KR20080047957A (en) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 Pharmaceutical composition for treatment and prevention of hypertension
JP2010515879A (en) * 2007-01-12 2010-05-13 オールプリオン・アーゲー Method for removing prion protein
KR101405823B1 (en) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 Pharmaceutical Composition for the Treatment and Prevention of glaucoma
KR20090071829A (en) * 2007-12-28 2009-07-02 주식회사 머젠스 Pharmaceutical composition for treatment and prevention of kidney diseases
KR20090073381A (en) * 2007-12-31 2009-07-03 주식회사 머젠스 Pharmaceutical composition for the treatment and prevention of cardiac disease
BRPI0910550A2 (en) * 2008-04-30 2015-09-29 Novartis Ag assay for pathogenic conformers
KR20100041277A (en) * 2008-10-13 2010-04-22 재단법인서울대학교산학협력재단 Seed-linked polymer support
KR20120102716A (en) * 2009-11-23 2012-09-18 팔라틴 테크놀로지스 인코포레이티드 Melanocortin-1 receptor-specific linear peptides
US20120009209A1 (en) * 2010-06-10 2012-01-12 The Regents Of The University Of California Enrichment and purification of infectious prion proteins
CN112337314B (en) * 2020-10-23 2022-04-29 湖南沁森高科新材料有限公司 Method for identifying oxidized polyamide membrane

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2128362T3 (en) * 1991-12-03 1999-05-16 Proteus Molecular Design FRAGMENTS OF PRION PROTEINS.
AU4376093A (en) * 1992-05-15 1993-12-13 Instituto Nazionale Neurologico C. Besta Soluble prion polypeptides, and methods for detecting and purifying thereof
AU667530B2 (en) * 1992-05-28 1996-03-28 New York Blood Center, Inc., The Removal of antibodies from blood-derived compositions while retaining coagulation factors
JPH08510325A (en) * 1993-05-28 1996-10-29 カイロン コーポレイション Methods for selecting biologically active peptide sequences
US5834318A (en) * 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
US5723579A (en) * 1996-02-02 1998-03-03 Bayer Corporation Fibrinogen binding peptides
US5808011A (en) * 1996-07-01 1998-09-15 Biopure Corporation Method for chromatographic removal of prions
IES980090A2 (en) * 1997-02-06 2001-08-22 Enfer Technology Ltd Immunological assay for spongiform encephalopathies
US6221614B1 (en) * 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
DE19741607A1 (en) * 1997-09-20 1999-03-25 Prionics Ag New polypeptides comprising prion protein sequences
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
US6750025B1 (en) * 1998-07-09 2004-06-15 V.I. Technologies, Inc. Method of detecting and isolating prion protein and variants thereof
CA2385743A1 (en) * 1999-09-28 2001-04-05 Universitat Zurich Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis
WO2001040265A2 (en) * 1999-12-02 2001-06-07 V.I. Technologies, Inc. Ligands for a target molecule and a method for indentifying them

Also Published As

Publication number Publication date
WO2001077687A2 (en) 2001-10-18
JP2003530554A (en) 2003-10-14
EP1272509A2 (en) 2003-01-08
US20040186273A1 (en) 2004-09-23
IL152116A0 (en) 2003-05-29
WO2001077687A3 (en) 2002-05-23
CA2405568A1 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
AU2001251358A1 (en) Prion-binding ligands and methods of using same
AU2001275441A1 (en) Filter arrangement and methods
AU2001245928A1 (en) Electrolyzer and method of using the same
AU2001280599A1 (en) Compounds and methods
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU7989400A (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU3215500A (en) Compounds and methods
AU2002314466A1 (en) Withasol and methods of use
AU2001286589A1 (en) Surface preparation agent and surface preparation method
AU2001243394A1 (en) Compounds and methods
AU2001260774A1 (en) Bio-support and preparing method of the same
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
HK1046646A1 (en) Preparations and method of producing the same
AU2002359694A1 (en) Compounds and methods
AUPQ872300A0 (en) Compounds and methods
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU1083501A (en) Antibiotic-metal complex and methods
AU2001278951A1 (en) Compounds and methods
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
EP1263935A4 (en) Scytonemin and methods of using thereof